Highlights

• Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI)
• DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5 billion in 2026,^[1] and no currently approved therapies for the disease which is associated with rapid decline in kidney function and high mortality rate
• Strong safety data package - a large Phase 1 clinical trial in 85 healthy participants demonstrated DMX-652 was well tolerated at both a single dose and multiple doses over 14 days, with no serious adverse events related to drug reported
• Promising pre-clinical efficacy data demonstrated to date, with strong scientific reasoning validating DMX-652's mechanism of action
• DMX-652 is first and best-in class drug candidate, with no known clinical stage competitors and a mechanism of action which has the potential to extend across multiple other indications
• Strong strategic alignment with ongoing ACTION3 Phase 3 FSGS rare kidney disease program and Dimerix's broader existing renal-focused pipeline, leveraging Dimerix's existing infrastructure and expertise
• Completion of ACTION3 trial for Dimerix's lead asset, DMX-200 in FSGS; up front acquisition payment for DMX-652 and initiation of Phase 2 clinical trial all funded (see ASX announcement 17 July 2026) with further non-dilutive funding discussions underway

MELBOURNE, Australia, July 17, 2026 /PRNewswire/ -- Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from Mission Therapeutics Limited ("Mission").